New research sees zebrafish earn their stripes in the fight against muscular dystrophy

October 13, 2015

New research published today in the journal eLife has demonstrated a new method for observing the behaviour of the protein Dystrophin in a living animal cell, in real-time. This breakthrough may provide a key to understanding how to treat the genetic disease, Muscular Dystrophy.

This, as yet incurable disease, is caused by a genetic mutation, with sufferers missing the Dystrophin protein in their muscle cells. In order to better understand the implications of this missing protein, a team of researchers from the University of Surrey and King's College London introduced human Dystrophin protein into the muscle cells of zebrafish embryos.

Using a new observational method developed by the University of Surrey, researchers successfully watched the movement of Dystrophin in the living cell. In achieving real-time observation of the protein, it is hoped scientists will gain better understanding of the role of Dystrophin in the human body. Ultimately this will assist in the development of future therapies.

"Muscular Dystrophy is an incurable genetic disease that causes much suffering as muscles waste away causing paralysis, and early death," explained Dr Richard Sear of the University of Surrey.

"Research has already shown that sufferers of the disease are missing Dystrophin but what we don't yet understand is exactly what this protein does in our bodies and why it is so important," he continued, "Our work has developed a new method for observing Dystrophin as it moves around a living cell, which has never been done before. Using this new method our colleagues at King's College London were then able to watch Dystrophin 'at work', which is very exciting and has implications for treating this awful disease."

"What they saw is that despite Dystrophin being about 30 times bigger than an average protein, it is extremely mobile. It moves rapidly, including at the tips of muscle cells, where we think it does its job. Now that scientists can observe it at work, we will be able to better understand Dystrophin's function in our bodies, and apply this understanding in gene therapy."

Zebrafish were chosen as their embryos are transparent and so by attaching a fluorescent tag, the Dystrophin molecules could be seen at work in the zebrafish's muscle cells.

"The next step for this research is to use this new method to observe different mutated versions of Dystrophin that are known to cause disease of different severities, to try to understand the link between these mutations and the disease. From there scientists will be closer to better smaller versions of the protein that can be used in gene therapy," concluded Dr Sear.

University of Surrey

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to